YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Gold-backed payments, enterprise AI, a Long COVID clinical readout and AI-powered school safety lead a 6:30 p.m. ET broadcast reaching audiences across the United States, Latin America and MENA NEW YORK CITY, NY / ACCESS Newswire / Septemb…
October 3 Southeast Asia launch will add distribution reaching approximately 68 million households NEW YORK CITY, NY / ACCESS Newswire / September 5, 2026 / New to The Street, the 18-year media brand serving public companies and companies…
Earnings Call Insights: Lantern Pharma (LTRN) Q2 2026 MANAGEMENT VIEW * “In August, we established Open Medicine AI as a separate company with commercial licenses and agreements with Lantern in place to take the AI data models to the next…
Image source: The Motley Fool. Date Thursday, March 27, 2025 at 4:30 p.m. ET Call participants President and CEO — Panna SharmaChief Financial Officer — David Margrave Need a quote from a Motley Fool analyst? Email pr@fool.com Takeaways LP…
Image source: The Motley Fool. Date Thursday, March 27, 2025 at 4:30 p.m. ET Call participants President and CEO — Panna Sharma Chief Financial Officer — David Margrave Need a quote from a Motley Fool analyst? Email pr@fool.com Full Confer…
The United States market has shown impressive growth, with a 1.1% increase over the last week and a substantial 27% rise over the past year, alongside expectations for earnings to grow by 17% annually in the coming years. Penny stocks, whi…
Gainers Quantum Cyber (NASDAQ:QUCY) shares rose 163.0% to $0.85 during Wednesday's regular session. The market value of their outstanding shares is at $4.0 million. Whitehawk Therapeutics (NASDAQ:WHWK) stock moved upwards by 29.59% to $5.0…
Earnings Call Insights: Lantern Pharma (LTRN) Q4 2025 MANAGEMENT VIEW * Panna Sharma, President, CEO & Director, highlighted, "2025 was a defining year for Lantern Pharma. We achieved clinical validation, we believe, across multiple progra…
(RTTNews) - Stock of Lantern Pharma Inc. (LTRN) is moving down about 10 percent on Friday morning trading after the company, along with its subsidiary Starlight Therapeutics, announced that the U.S. Food and Drug Administration has cleared…
Featured Companies Include FreeCast (NASDAQ:CAST), KLED.ai, Lantern Pharma (NASDAQ:LTRN), and BlackBarn Restaurant NEW YORK CITY, NY / ACCESS Newswire / March 21, 2026 / New to The Street, one of the longest-running U.S. and international…
Lantern Pharma, Inc. (NASDAQ:LTRN) is one of the best AI penny stocks to buy right now. On January 20, the FDA granted Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-284 an Orphan Drug Designation (ODD). LP-284 is an investigational small-molecul…
The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalonta…
(RTTNews) - Lantern Pharma Inc. (LTRN) announced Tuesday that its Phase 1a study evaluating the drug candidate LP-184 in patients with advanced solid tumors, including Glioblastoma Multiforme (GBM), an aggressive form of brain cancer, met…
AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The…
DALLAS - Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biotech company currently trading at $4.01, has completed patient enrollment for its Phase 2 HARMONIC clinical trial in Japan ahead of schedule, the company announced Thursday in…
Lantern Pharma Inc . (NASDAQ:LTRN) announced that its board of directors appointed Lee T. Schalop, M.D. to the board, effective Thursday. The appointment was made following a recommendation from the board’s Nominating and Corporate Governa…
DALLAS - Lantern Pharma Inc. (NASDAQ:LTRN), an AI-driven oncology drug development company with a current market capitalization of $45.67 million, announced Monday the appointment of Lee T. Schalop, MD, to its Board of Directors. The compa…
DALLAS - Lantern Pharma Inc. (NASDAQ:LTRN), a $43.46 million market cap biotech company whose stock has gained 26.33% year-to-date, announced Wednesday that a patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell…
Lantern Pharma (NASDAQ:LTRN [https://seekingalpha.com/symbol/LTRN]) Monday said [https://seekingalpha.com/pr/20171807-lantern-pharma-secures-eu-patent-allowance-for-lpminus-284-bolstering-global-ip-position-for]that the European Patent Off…
FORT WORTH, Texas— Lantern Pharma Inc . (NASDAQ:LTRN) witnessed a notable stock sale by a major shareholder, as disclosed in a recent SEC filing. The timing is particularly interesting as InvestingPro data shows the stock has declined over…
It’s easy to understand why investors remain curious about AI penny stocks in December and beyond. Leading companies in the artificial intelligence (AI) industry have multiplied in value in 2023. The AI market was worth roughly $515 billio…
Dive into the dynamic realm of undervalued AI penny stocks, offering robust long-term upside potential. By 2030, artificial intelligence (AI) is set to fuel the global economy with a staggering $15.7 trillion injection. Big tech is riding…
Let’s take a look at some of the top AI stocks in August 2023. For the most part, the average investor is familiar with the major names in the sector, such as Nvidia (NASDAQ:NVDA) and Microsoft (NASDAQ:MSFT). All thanks to their pioneering…
New podcast series shines a spotlight on undervalued small-cap and microcap stocks ORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap compa…
Webcast to be held Wednesday, August 9, 4:30 p.m. ET, register here, or at the link below. DALLAS, August 02, 2023--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and tran…
The era of artificial intelligence is upon us. By 2030, AI is expected to contribute $15.7 trillion to the global economy. And while many of the large-cap tech giants are making a splash, it’s frequently the smallest companies that produce…
DALLAS, July 17, 2023--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platfo…
Non-Hodgkin’s lymphoma (NHL) is the seventh leading cause of cancer in the US, with 20-40% of patients experiencing relapsed or refractory disease with limited or no therapeutic options. Publication highlights in vitro and in vivo results…
LP-184 is a novel, synthetically-lethal, small molecule that has been developed using insights from Lantern’s AI platform, RADR®. The first-in-human Phase 1A clinical trial has been cleared to proceed by the FDA and is anticipated to launc…
Lantern will leverage its proprietary AI platform, RADR®, to rapidly develop novel cryptophycin-antibody drug conjugates (ADCs), which represent an exciting class of potent and highly targeted drug candidates. The collaboration with Bielef…
AI penny stocks offer investors a thrilling opportunity to tap into the fast-evolving artificial intelligence space. AI penny stocks have limited financial resources and modest profits, but their long-term growth prospects are enticing. AI…
DALLAS, May 17, 2023--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning ("ML") platform to transform the cost, pa…
By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT 2022 Financial and Operational Results On May 9, 2023, Lantern Pharma, Inc. (NASDAQ:LTRN) announced 2022 financial and operational results, filed its Form 10-Q with t…
Dosed first patient in the Phase 2 Harmonic™ clinical trial; a study for the unique population of non-small lung cancer patients who are never-smokers and who make up 15-20% of all lung cancer cases. Submission of the IND application for L…
BELTSVILLE, Md., May 3, 2023 /PRNewswire/ -- Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled "A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with…
Webcast to be held Tuesday, May 9, 4:30 p.m. ET, register here, or at the link below. DALLAS, May 02, 2023--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artific…